NCT07077798View on ClinicalTrials.gov

Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver Resection

NANot yet recruitingINTERVENTIONAL
Enrollment

234

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

December 31, 2027

Conditions
Hepatocellular Carcinoma (HCC)
Interventions
DRUG

Sintilimab

Patient receives first adjuvant sintilimab 2-4 weeks postoperatively, 200 mg IV, every 21 days for a total of 8 cycles

DRUG

Lenvatinib

lenvatinib is initiated orally(12 mg for body weight \>= 60kg, 8 mg for body weight \< 60kg daily), 2-4 weeks postoperatively for 6 months.

All Listed Sponsors
lead

Wan-Guang Zhang

OTHER

NCT07077798 - Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver Resection | Biotech Hunter | Biotech Hunter